National Psoriasis Foundation


Shortage of injectable methotrexate

The Food and Drug Administration (FDA) announced a shortage of injectable methotrexate, a chemotherapy drug that was approved in the 1970s to treat severe psoriasis and psoriatic arthritis. The shortage does not affect the supply of methotrexate tablets, which is the most common version of methotrexate prescribed by dermatologists for psoriasis treatment.

The National Psoriasis Foundation recommends that people concerned about the shortage of injectable methotrexate products speak with their doctors about treatment options.

Learn more about methotrexate for psoriasis »

February 14, 2012

National Psoriasis Foundation Our Mission: To drive efforts to cure psoriatic disease and improve the lives of those affected.